Eli Lilly Commits $350M Upfront and Acquires Orna Therapeutics for $2.4B
Eli Lilly will pay $350 million upfront to collaborate on novel biotech development in China, with further potential milestone and royalty payments. The company also agreed to acquire cell therapy specialist Orna Therapeutics for up to $2.4 billion to strengthen its RNA-based pipeline and global R&D footprint.
1. $350M China Biotech Collaboration
On Feb. 9, Eli Lilly agreed to invest $350 million upfront in a collaboration with a Chinese biotechnology firm to co-develop novel therapeutic candidates. The deal grants Lilly development and commercialization rights in Greater China and includes undisclosed milestone and royalty mechanisms tied to product approvals and sales.
2. Orna Therapeutics Acquisition
Lilly will acquire cell therapy specialist Orna Therapeutics for up to $2.4 billion in cash, comprising an undisclosed upfront payment plus development and commercial milestones. The transaction aims to integrate Orna’s RNA-based modality into Lilly’s pipeline, accelerating early-stage programs across oncology and rare diseases.